Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Equity Average (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Equity Average for 15 consecutive years, with $145.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 13.05% to $145.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $145.1 million, a 13.05% decrease, with the full-year FY2025 number at $148.7 million, down 18.78% from a year prior.
  • Equity Average was $145.1 million for Q4 2025 at Anika Therapeutics, down from $147.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $288.6 million in Q4 2021 to a low of $145.1 million in Q4 2025.
  • A 5-year average of $236.0 million and a median of $273.4 million in 2021 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: increased 4.34% in 2022, then tumbled 30.84% in 2024.
  • Anika Therapeutics' Equity Average stood at $288.6 million in 2021, then decreased by 1.15% to $285.2 million in 2022, then fell by 15.38% to $241.4 million in 2023, then crashed by 30.84% to $166.9 million in 2024, then decreased by 13.05% to $145.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Equity Average are $145.1 million (Q4 2025), $147.2 million (Q3 2025), and $148.0 million (Q2 2025).